Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12830946 | 0.91 | THRB (0.40) | ANO1DHODHANO2THRB | |
| SCHEMBL12756319 | 0.86 | ANO1 (0.38) | ANO1ANO2THRBMEN1KMT2A | |
| SCHEMBL12270901 | 0.84 | ANO1 (0.59) | ANO1ANO2MEN1KMT2A | |
| SCHEMBL12756328 | 0.83 | ANO1 (0.37) | ANO1DHODHRXFP1 | |
| SCHEMBL12831073 | 0.81 | ANO1 (0.43) | ANO1DHODHANO2THRBTP53 | |
| SCHEMBL15480680 | 0.81 | DHODH (0.44) | ANO1DHODHANO2THRB | |
| SCHEMBL12831071 | 0.80 | MAPT (0.43) | ANO1THRBMEN1KMT2ATP53 | |
| SCHEMBL12756310 | 0.80 | ANO1 (0.38) | ANO1DHODHMEN1KMT2ATP53 | |
| SCHEMBL12756301 | 0.79 | ABL1 (0.41) | ANO1MEN1KMT2A | |
| SCHEMBL12830017 | 0.78 | KDM4E (0.45) | ANO1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885DHODH 2153/4885ANO2 98/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885DHODH 2153/4885ANO2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.